U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07712679) titled 'Evaluation of Kidney Fibrosis Via FAPI PET/CT' on July 02.
Brief Summary: Interstitial fibrosis is a hallmark of progression in chronic kidney disease (CKD), yet it can presently be assessed only by kidney biopsy, which is invasive and prone to sampling error.
In recent years the advances in molecular imaging, especially high spatial and temporal resolution of the scanners and the development of radiopharmaceuticals to visualize metabolic processes or immune cells have been significant, opening promising possibilities in multiple fields. It was demonstrated that in autoimmune diseases as Crohns disease the use of fibrosis markers, ...